Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

607 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Lester DK, et al. Among authors: messina j. Nat Cancer. 2023 Feb;4(2):222-239. doi: 10.1038/s43018-022-00506-7. Epub 2023 Jan 23. Nat Cancer. 2023. PMID: 36690875 Free PMC article.
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Paraiso KH, et al. Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26. Cancer Discov. 2015. PMID: 25542447 Free PMC article.
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.
Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Eroglu Z, et al. Among authors: messina jl. Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19. Clin Cancer Res. 2018. PMID: 29674508 Free PMC article. Clinical Trial.
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, Kim Y, Wu J, Chalfant CE, Kim M. Hill KS, et al. Among authors: messina jl. Mol Cancer Res. 2019 Feb;17(2):583-593. doi: 10.1158/1541-7786.MCR-18-0777. Epub 2018 Oct 24. Mol Cancer Res. 2019. PMID: 30355677 Free PMC article.
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. Atay C, et al. Among authors: messina jl. Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14. Clin Cancer Res. 2019. PMID: 30765391 Free PMC article.
607 results